Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

Timothy G. Kuzel; Jia Fu; Mark Anderson; Michael Stec; Michael Boler; Dylan Behun; Amy Gosha; Gavin Cloherty; Alan Landay; James Moy

doi:10.1016/j.vaccine.2022.12.049

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

Timothy G. Kuzel, Jia Fu, Mark Anderson, Michael Stec, Michael Boler, Dylan Behun, Amy Gosha, Gavin Cloherty, Alan Landay, James Moy

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-naïve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-naïve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-naïve and previously-infected individuals.

Original language	English (US)
Pages (from-to)	879-882
Number of pages	4
Journal	Vaccine
Volume	41
Issue number	4
DOIs	https://doi.org/10.1016/j.vaccine.2022.12.049
State	Published - Jan 23 2023
Externally published	Yes

Keywords

Antibodies
Booster
Hybrid Immunity
Omicron
SARS-CoV-2
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2022.12.049

Cite this

Kuzel, T. G., Fu, J., Anderson, M., Stec, M., Boler, M., Behun, D., Gosha, A., Cloherty, G., Landay, A., & Moy, J. (2023). Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals. Vaccine, 41(4), 879-882. https://doi.org/10.1016/j.vaccine.2022.12.049

Kuzel, TG, Fu, J, Anderson, M, Stec, M, Boler, M, Behun, D, Gosha, A, Cloherty, G, Landay, A & Moy, J 2023, 'Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals', Vaccine, vol. 41, no. 4, pp. 879-882. https://doi.org/10.1016/j.vaccine.2022.12.049

@article{c9e5365b3b45493591cf6da7ecfdf1e5,

title = "Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-na{\"i}ve and previously-infected individuals",

abstract = "It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-na{\"i}ve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-na{\"i}ve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-na{\"i}ve and previously-infected individuals.",

keywords = "Antibodies, Booster, Hybrid Immunity, Omicron, SARS-CoV-2, Vaccine",

author = "Kuzel, {Timothy G.} and Jia Fu and Mark Anderson and Michael Stec and Michael Boler and Dylan Behun and Amy Gosha and Gavin Cloherty and Alan Landay and James Moy",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2023",

month = jan,

day = "23",

doi = "10.1016/j.vaccine.2022.12.049",

language = "English (US)",

volume = "41",

pages = "879--882",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

AU - Kuzel, Timothy G.

AU - Fu, Jia

AU - Anderson, Mark

AU - Stec, Michael

AU - Boler, Michael

AU - Behun, Dylan

AU - Gosha, Amy

AU - Cloherty, Gavin

AU - Landay, Alan

AU - Moy, James

PY - 2023/1/23

Y1 - 2023/1/23

N2 - It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-naïve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-naïve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-naïve and previously-infected individuals.

AB - It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases Omicron neutralization. We compared Spike-binding IgG responses against wild type virus and four SARS-CoV-2 Omicron subvariants in infection-naïve and previously-infected (hybrid immunity) individuals after the second and the third (booster) dose of BNT162b2. In both groups of individuals, antibodies for all four Omicron subvariants were lower than wild type antibodies. Compared to infection-naïve individuals, hybrid immunity resulted in higher antibodies levels after 2 doses of vaccine but not after the booster. In both groups, antibodies for wild type and all Omicron subvariants waned over an 8-month period post second dose but rebounded after the booster. These results underscore the importance of boosters to restore diminishing antibody levels for both infection-naïve and previously-infected individuals.

KW - Antibodies

KW - Booster

KW - Hybrid Immunity

KW - Omicron

KW - SARS-CoV-2

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85146682097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146682097&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2022.12.049

DO - 10.1016/j.vaccine.2022.12.049

M3 - Article

C2 - 36572601

AN - SCOPUS:85146682097

SN - 0264-410X

VL - 41

SP - 879

EP - 882

JO - Vaccine

JF - Vaccine

IS - 4

ER -

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this